Cetya Therapeutics, Inc.

300 W. Drake Road
Fort Collins, CO 80523

Contact:	John Pilon, Acting CEO	**Email:**	jpilon@cetyacorp.com
Website:	www.cetya-therapeutics.com	**Founded:**	2012
Telephone:	970-989-9402	**Employees:**	2

Description of Company:

CETYA Therapeutics was founded in July of 2012 to commercialize analogs of the class I isoform selective histone deacetylase inhibitor (HDACi) largazole developed by Colorado State University Distinguished Professor Dr. Robert Williams and Dr. James Bradner of the Dana Farber Cancer Institute. A recently awarded composition of matter patent protects potent largazole analogs that have outstanding isoform selectivity and "drugability". CETYA plans to create a drug discovery platform whereby the isoform selectivity and broad-spectrum clinical utility of the technology is leveraged into a drug pipeline targeting unmet medical needs, especially in oncology, neurodegeneration, autoimmunity, and hemoglobinopathies.

Market:

Small-molecule targeted cancer therapy revenues are expected to reach $27.3 billon (USD) worldwide by 2015. Over 13 million patients were diagnosed with cancer in 2009, a number that is expected to grow to over 20 million by 2025. As there are still significant deaths from cancers of all types, new therapeutic agents that prolong survivorship and enhance the quality of life of cancer patients are needed. In addition to antineoplastic indications, CETYA will pursue application of its selective HDACi platform to autoimmune and neuropathy based conditions, such as multiple sclerosis (MS). The annual worldwide market for the four main MS drugs is greater than $10 billion (USD) CETYA Therapeutics will look to partner its pipeline with fully integrated pharmaceutical companies (FIPCOs) to generate revenue via upfront, milestone, and royalty payments in return for the rights to develop and commercialize CETYA discovered drugs.

CETYA Therapeutics isoform selective HDACi's target genes that have been turned off due to biochemical modification of the proteins that package DNA, a process called epigenetic regulation. Many of the non-selective HDACi's in clinical development have been limited by off-target activity leading to undesirable side effects in the patient. Therefore isoform selective HDACi's are generally accepted by biopharma leaders as next generation epigenetic-based medicines (epipharmaceuticals) that will improve the clinical limitations observed with non-selective-HDACi's.

Management:

- Dr. John L. Pilon III, Acting CEO (15 years of experience in applied R&D in biopharma and biotech)
- Dr. Robert M. Williams, President (world renowned natural product chemist and start-up veteran)
- Dr. Terry Opgenorth, Chairman of the Board (former DVP Abbott Drug Discovery and VP CSU Ventures)

Recent Milestones:

- Exclusive rights to composition of matter patent in-licensed from CSU Ventures, second patent filed to expand IP position of key molecules.

Financing:

Several SBIR and other non-dilutive grant applications are in preparation. Currently seeking $500,000 in seed capital to pursue proof-of-concept animal studies for lead compound development.